Second-Line Treatment With Axitinib: An Effective and Well-Tolerated Weapon in the Therapeutic Sequence of Clear Cell Renal Cell Carcinoma. Work Paper Public Hlth 2015, 4 (1). https://doi.org/10.4081/wpph.2015.6697.